PMA device
BioMimics 3D Vascular Stent System
Veryan Medical, Ltd. · Stent, Superficial Femoral Artery (NIP, Class III) · First FDA decision Oct 4, 2018, newest Jun 26, 2025Peripheral artery disease
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
4
PMA pathway
Device trials
6
Naming "BioMimics 3D"
MAUDE reports
609
Brand "BioMimics 3D", since 2015
PubMed studies
11
Mentioning "BioMimics 3D"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing BioMimics 3D Vascular Stent System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 4 of 4 decisions filed under this name.
- BioMimics 3D Vascular Stent SystemPMA supplement
P180003-S012 · Decided Jun 26, 2025 · 203 days after receipt · Normal 180 Day Track
Device type: STENT, SUPERFICIAL FEMORAL ARTERY (NIP) · Cardiology
3 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R8Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R7Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R6Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R3Updated Sep 21, 2026
- Carotid Artery Stenting in Post-Approval StudiesNational analysisReview closedCAG-00259NUpdated Sep 17, 2026
- Carotid Artery StentingNational analysisReview closedCAG-00085RUpdated Sep 17, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085NUpdated Sep 15, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "BioMimics 3D", any status and sponsor, newest update first.
Veryan Medical Ltd.Not on our public-company list
NCT02900924 · 507 participants · Start Sep 2016 · Primary completion Oct 2019
Device: BioMimics 3D Stent · For: Peripheral Arterial Disease
Sites: Aalst, Belgium; Antwerp, Belgium; Dendermonde, Belgium · 23 sites in all
5 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "BioMimics 3D", and for the whole product code for context.
This brand
609 reports: 117 malfunction, 492 injury, 0 death
Whole product code NIP
9,363 reports: 4,911 malfunction, 4,303 injury, 147 death
Newest reports for this brand
- BioMimics 3D Vascular Stent SystemMalfunction
3011632150-2026-00033 · Received Oct 7, 2026 · Event dated Sep 1, 2026
Device type: Stent, Superficial Femoral Artery (NIP)
Device problem as coded: Break
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "BioMimics 3D"[tiab]. The summary above synthesizes these.
- BioMimics 3D Stent in Femoropopliteal Lesions: 3-Year Outcomes with Propensity Matching for Drug-Coated Balloons.
Piorkowski M, Zeller T, Rammos C, et al. · J Cardiovasc Dev Dis · 2023
- BioMimics 3D vascular stent system for femoropopliteal interventions.
Lichtenberg M, Zeller T, Gaines P, et al. · Vasa · 2022Multicenter Study
- Evaluation of Femoropopliteal In-Stent Restenosis Characteristics Stratified by Stent Design.
Noory E, Böhme T, Salm J, et al. · J Clin Med · 2023
- The BioMimics 3D Helical Centreline Nitinol Stent in Chronic Limb Threatening Ischaemia and Complex Lesions: Three Year Outcomes of the MIMICS-3D Registry.
Rammos C, Zeller T, Piorkowski M, et al. · Eur J Vasc Endovasc Surg · 2024Multicenter Study, Observational Study
- BioMimics 3D Stent Graft System in Chronic Limb Threatening Ischaemia and Complex Femoropopliteal Lesions: The New Dimension in Complex Endovascular Interventions?
Teraa M, von Allmen RS · Eur J Vasc Endovasc Surg · 2024Case Reports
- Treatment of Femoropopliteal Lesions With the BioMimics 3D Vascular Stent System: Two-Year Results From the MIMICS-2 Trial.
Sullivan TM, Zeller T, Nakamura M, et al. · J Endovasc Ther · 2021Clinical Trial
- Swirling Flow and Wall Shear: Evaluating the BioMimics 3D Helical Centerline Stent for the Femoropopliteal Segment.
Sullivan TM, Zeller T, Nakamura M, et al. · Int J Vasc Med · 2018Review
- Helical Centerline Stent Improves Patency: Two-Year Results From the Randomized Mimics Trial.
Zeller T, Gaines PA, Ansel GM, et al. · Circ Cardiovasc Interv · 2016Comparative Study, Multicenter Study
- Deformation of the Femoropopliteal Segment: Effect of Stent Length, Location, Flexibility, and Curvature.
Ní Ghriallais R, Heraty K, Smouse B, et al. · J Endovasc Ther · 2016Comparative Study, Research Support, Non-U.S. Gov't
- Biomimetic Stents for Infrainguinal Peripheral Arterial Disease: Systematic Review and Meta-Analysis.
Messeder SJ, López-Peña G, Pepper C, et al. · Eur J Vasc Endovasc Surg · 2024Meta-Analysis, Systematic Review
- Cost-effectiveness of superficial femoral artery endovascular interventions in the UK and Germany: a modelling study.
Kearns BC, Thomas SM · BMJ Open · 2017Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code NIP.
- GORE VIABAHN EndoprosthesisW. L. Gore & Associates, Inc. · PMA 2022
- Supera Peripheral Stent SystemAbbott Vascular (Idef Technologies Inc) · PMA 2025
- LifeStent Vascular Stent SystemBard Peripheral Vascular, Inc. · PMA 2023
- Everflex Self-Expanding Peripheral Stent System (Everflex)Medtronic Vascular, Inc. · PMA 2025
- Innova Vascular Self-Expanding Stent SystemBoston Scientific Corporation · PMA 2021
- Bard Lifestent Vascular Stent SystemBard Peripheral Vascular, Inc. · PMA 2016
- Astron Pulsar and Pulsar-18 Stent SystemsBiotronik AG · PMA 2018
- Misago Peripheral Self-Expanding Stent SystemTerumo Medical Corporation · PMA 2017
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.